A further research direction under consideration is to explore the therapeutic potential of PPAR pan-agonists that would combine the agonistic activities toward PPARγ, PPARα, and PPARδ in a single ligand but with a balanced activation profile; these compounds may prove to be the ultimate combination of PPAR activities for treatment of type 2 diabetes and its further complications. This evidence concerns the gene PPARA and type 2 diabetes mellitus.